Contraindicated (1)bortezomib will increase the level or outcome of mavacamten by affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Robust or moderate CYP2C19 inhibitors might improve mavacamten systemic exposure, causing coronary heart failure as a consequence of systolic dysfunction.Lab and/or professional medical exams (which include